Curated metabolic health research from PubMed and leading YouTube channels
Subscribe via RSSShowing 1-12 of 19 articles
Nick Norwitz discusses the groundbreaking VERVE-102 gene editing therapy for LDL cholesterol reduction, highlighting its potential impact on metabolic health.
A recent trial demonstrates the potential of gene editing in liver health, paving the way for innovative metabolic therapies beyond LDL reduction.
Recent discussions highlight the importance of rigorous research in understanding metabolic health. This article delves into the implications of ongoing studies and their relevance to biomarkers.
Dave Feldman discusses the Cleerly anomalies and their implications for metabolic health, highlighting the need for clarity amidst ongoing debates.
A recent study found a 62% reduction in LDL cholesterol at the highest dose, though cardiovascular outcomes were not improved. This raises important questions about long-term safety and metabolic health.
A groundbreaking study reveals gene editing can reduce LDL cholesterol by 62%, sparking debate on its implications for heart disease and metabolic health.
A recent Phase 1 trial tested VERVE-102, a gene-editing therapy for patients with familial hypercholesterolemia, highlighting its potential in lipid management.
The #CholesterolCode is igniting global discussions on cholesterol's role in metabolic health, emphasizing low-carb lifestyles and their benefits.
This study uncovers genetic links between lipid metabolism and multiple sclerosis severity, highlighting the role of PUFA pathways. Understanding these connections can inform metabolic health strategies.
VERVE-102 employs cutting-edge gene editing to target the PCSK9 gene, potentially transforming lipid metabolism and cardiovascular health. This innovative approach highlights the importance of effective delivery in gene therapy.
A recent study reveals how interferon responses in COVID-19 patients impact metabolic health, highlighting the connection between inflammation and lipid metabolism.
New research reveals how lipogenesis-driven EGFR palmitoylation aids immune evasion in TNBC, suggesting FASN inhibitors could enhance anti-tumor immunity.